Q4 2025 · 13F-HR
Frazier Life Sciences Management, L.P.holdings as filed
Filed 2026-02-13 · accession 0001892134-26-000001
$3.72B
Reported value
40
Positions
2025-12-31
Period end
The Brief · Frazier Life Sciences Management, L.P. · Q4 2025
AI · grounded in 13F
Frazier Life Sciences Management, L.P. closed its position in VRNA, reducing exposure by $361.1M. The fund established new positions in RAPT and VOR, investing $33.3M and $33.3M respectively. Additionally, the fund increased its holdings in RNAGBP by 57.3% and DYN by 16%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N62509109 | NAMS | NEWAMSTERDAM PHARMA COMPANY | $594.4M | 16.0% | 16,943,774 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $536.7M | 14.4% | 6,795,121 | Common | SOLE |
| 03969K108 | ARQT | ARCUTIS BIOTHERAPEUTICS INC | $286.8M | 7.70% | 9,874,511 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $271.2M | 7.28% | 3,545,557 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $209.8M | 5.64% | 6,652,013 | Common | SOLE |
| 71722W107 | PHAT | PHATHOM PHARMACEUTICALS INC | $206.8M | 5.55% | 12,466,489 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $189.2M | 5.08% | 4,567,274 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $128.4M | 3.45% | 10,259,409 | Common | SOLE |
| 501147102 | KRYS | KRYSTAL BIOTECH INC | $120.4M | 3.23% | 488,460 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $100.1M | 2.69% | 1,260,000 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $84.6M | 2.27% | 22,729,436 | Common | SOLE |
| 483497103 | KALV | KALVISTA PHARMACEUTICALS INC | $81.4M | 2.19% | 5,039,867 | Common | SOLE |
| 697947109 | PVLA | PALVELLA THERAPEUTICS INC NE | $75.6M | 2.03% | 722,400 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $70.9M | 1.90% | 983,125 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $63.5M | 1.71% | 797,455 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $61.7M | 1.66% | 3,153,082 | Common | SOLE |
| 87650L103 | TARS | TARSUS PHARMACEUTICALS INC | $59.7M | 1.60% | 728,644 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $59.5M | 1.60% | 9,862,301 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $59.4M | 1.60% | 934,642 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA | $51.0M | 1.37% | 378,300 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $43.9M | 1.18% | 4,424,725 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $34.8M | 0.94% | 1,279,754 | Common | SOLE |
| 004225108 | ACAD | ACADIA PHARMACEUTICALS INC | $34.6M | 0.93% | 1,297,198 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $33.6M | 0.90% | 1,902,320 | Common | SOLE |
| 75382E208 | RAPT | RAPT THERAPEUTICS INC | $33.3M | 0.89% | 983,333 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $33.3M | 0.89% | 2,543,939 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S | $28.4M | 0.76% | 133,333 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $27.8M | 0.75% | 5,100,000 | Common | SOLE |
| 56400P706 | MNKD | MANNKIND CORP | $24.0M | 0.64% | 4,225,000 | Common | SOLE |
| 92025Y103 | VALN | VALNEVA SE | $20.2M | 0.54% | 2,291,666 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $19.6M | 0.53% | 700,647 | Common | SOLE |
| 30052C107 | EOLS | EVOLUS INC | $17.5M | 0.47% | 2,630,665 | Common | SOLE |
| 45258D105 | IMCR | IMMUNOCORE HLDGS PLC | $13.4M | 0.36% | 384,782 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA COMPANY | $11.5M | 0.31% | 500,333 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $9.2M | 0.25% | 241,592 | Common | SOLE |
| 05280R100 | AUTL | AUTOLUS THERAPEUTICS PLC | $9.2M | 0.25% | 4,623,324 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS INC | $5.3M | 0.14% | 3,868,750 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $4.9M | 0.13% | 521,000 | Common | SOLE |
| 98422T100 | XLO | XILIO THERAPEUTICS INC | $3.8M | 0.10% | 5,915,091 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $3.8M | 0.10% | 1,953,467 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.